Furthermore, we investigated the detailed mechanisms of the actions of Regorafenib, CHOP, and METTL14-m6A in the selected HCC cells, providing valuable insights for the treatment of HCC. This evidence concerns the gene DDIT3 and hepatocellular carcinoma.